Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit

Kits available in September for distribution

LONDON, September 20, 2022 /PRNewswire/ — Virax Biolabs (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection and diagnosis of viral diseases, today announced the distribution of ‘a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are intended for use in healthcare settings and can help healthcare professionals accurately identify monkeypox infection in people suspected of carrying the monkeypox virus with results generally available in 15 minutes. It also serves as a valuable initial screening test for people who have been exposed to monkeypox-infected patients or a high-risk environment. Specialized diagnostic kits can be found by contacting company sales representatives.

Chairman of the Board of Directors and Managing Director of Virax, James Foster commented “I am very proud of our organization’s ability to bring this rapid antigen test kit to market quickly to help fight the monkeypox outbreak. We are working diligently to distribute the kits as well as detection previously announced Real-Time PCR of Monkeypox and Varicella Zoster Virus Kits into the hands of healthcare practitioners as quickly as possible.”

Monkeypox virus antigen rapid test kits are used for the qualitative in vitro detection of monkeypox virus antigen in oropharyngeal (throat) swabs and human skin exudates by colloidal gold immunochromatography.

About Virax Biolabs Group Limited

Founded in 2013, Virax Biolabs Group Limited is an innovative diagnostics company focused on the prevention, detection and diagnosis of viral diseases, with a particular focus on the field of immunology.

In addition to distributing a range of viral tested children in unique geographies, Virax Biolabs Group Limited is currently developing proprietary T cell testing technology with the aim of providing an immunological profiling platform that assesses the immune risk profile of each individual against the main global viral threats. The T cell test can be particularly effective in the diagnosis and therapy of COVID-19 as well as other threats such as monkeypox, hepatitis B, malaria, herpes, and human papillomavirus. For more information, please visit www.viraxbiolabs.com.

Safe Harbor Statement

This press release contains forward-looking statements. Additionally, from time to time, we or our representatives may make oral or written forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from information currently available to us. These forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings growth; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use words such as “may”, “should”, “expect”, “anticipate”, “intend”, “estimate “, “believes”, “”plans”, “projected”, “predicted”, “potentials” or “hopes” or the negative form of these terms or other similar terms. In evaluating these forward-looking statements, you You must consider a variety of factors, including: our ability to change the direction of the Company; our ability to keep pace with new technologies and changing market needs; and the competitive environment in which our business operates. others may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives. such times may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are under no obligation to publicly update or revise any forward-looking statement, whether due to uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur. .

SOURCE Virax Biolabs